Cargando…

Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2–Exposed CoronaVac-Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study

Real-world data on heterologous boosting with messenger RNA (mRNA)-1273 (Moderna) after inactivated COVID-19 vaccination are limited. We report mRNA-1273 boosting in heavily SARS-CoV-2–exposed Indonesian health-care workers who received a two-dose CoronaVac 6 months prior. Between August and Novembe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinto, Robert, Utomo, Dwi, Suwarti, Nelwan, Erni J., Surendra, Henry, Natasha, Cindy, Fransiska, Theresia, Deborah, Ranitria, Adella Faiqa, Subekti, Decy, Nuraeni, Nunung, Handayani, Winahyu, Rahardjani, Mutia, Baird, J. Kevin, Dunachie, Susanna, Shankar, Anuraj H., Hamers, Raph L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Tropical Medicine and Hygiene 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833072/ https://www.ncbi.nlm.nih.gov/pubmed/36450232 http://dx.doi.org/10.4269/ajtmh.22-0256

Ejemplares similares

Evaluating Saliva Sampling with Reverse Transcription Loop-mediated Isothermal Amplification to Improve Access to SARS-CoV-2 Diagnosis in Low-Resource Settings
por: Suwarti, Suwarti, et al.
Publicado: (2022)

Screening of methicillin-resistant Staphylococcus aureus nasal colonization among elective surgery patients in referral hospital in Indonesia
por: Nelwan, Erni J., et al.
Publicado: (2018)

Validation of the Nelwan Score as a screening tool for the diagnosis of typhoid fever in adults in Indonesia
por: Nelwan, Erni Juwita, et al.
Publicado: (2023)

A qualitative study of barriers to antimicrobial stewardship in Indonesian hospitals: governance, competing interests, cost, and structural vulnerability
por: Limato, Ralalicia, et al.
Publicado: (2022)

Optimizing antibiotic use in Indonesia: A systematic review and evidence synthesis to inform opportunities for intervention
por: Limato, Ralalicia, et al.
Publicado: (2022)

Blood culture utilization and epidemiology of antimicrobial-resistant bloodstream infections before and during the COVID-19 pandemic in the Indonesian national referral hospital
por: Sinto, Robert, et al.
Publicado: (2022)

Recent advances in the diagnosis of intestinal tuberculosis
por: Maulahela, Hasan, et al.
Publicado: (2022)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria
por: Satyagraha, Ari Winasti, et al.
Publicado: (2021)

Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study
por: Medina-Pestana, José, et al.
Publicado: (2021)

A multicentre point prevalence survey of patterns and quality of antibiotic prescribing in Indonesian hospitals
por: Limato, Ralalicia, et al.
Publicado: (2021)

Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
por: Nantanee, Rapisa, et al.
Publicado: (2022)

Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study
por: Medina-Pestana, José, et al.
Publicado: (2021)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia
por: Nelwan, Erni J., et al.
Publicado: (2015)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria
por: Baird, J. Kevin, et al.
Publicado: (2018)

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
por: Soysal, Ahmet, et al.
Publicado: (2021)

Perceptions, views and practices regarding antibiotic prescribing and stewardship among hospital physicians in Jakarta, Indonesia: a questionnaire-based survey
por: Limato, Ralalicia, et al.
Publicado: (2022)

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial
por: Leung, Nancy H L, et al.
Publicado: (2023)

Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells
por: Baird, J. Kevin, et al.
Publicado: (2015)

The how’s and what’s of vaccine reactogenicity
por: Hervé, Caroline, et al.
Publicado: (2019)

Association of G6PD status and haemolytic anaemia in patients receiving anti-malarial agents: a systematic review and meta-analysis
por: Nelwan, Erni J., et al.
Publicado: (2023)

Methods for predicting vaccine immunogenicity and reactogenicity
por: Gonzalez-Dias, Patrícia, et al.
Publicado: (2019)

Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies
por: Morales-Núñez, José Javier, et al.
Publicado: (2022)

Approach to the Patient With Malaria
por: Baird, J. Kevin, et al.
Publicado: (2019)

Vancomycin-Resistant Staphylococcus Aureus Infection Post-Liposuction in South Korea
por: Nelwan, Erni J, et al.
Publicado: (2021)

Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity in Q Fever Vaccine Development
por: Fratzke, Alycia P., et al.
Publicado: (2022)

Higher cut-off serum procalcitonin level for sepsis diagnosis in metastatic solid tumor patients
por: Aziz, Segal Abdul, et al.
Publicado: (2018)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
por: Briggs, Farren Basil Shaw, et al.
Publicado: (2021)

Reactogenicity to COVID-19 vaccination in the United States of America
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Editorial: Non-reactogenic vaccines against Q-fever
por: Gregory, Anthony E., et al.
Publicado: (2023)

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV
por: Motta, Edwiges, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o77emvpirc3n5qpc5flcmvd96i